Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy

Journal of Viral Hepatitis

Volumn 9, Issue 4, 2002, Pages 288-294

  Tabone, Marco ^a   Sidoli, L ^a   Laudi, C ^a   Pellegrino, S ^a   Rocca, G ^b   Della Monica, P ^a   Fracchia, M ^a   Galatola, G ^a   Molinaro, G C ^a   Arico S ^a   Pera, A ^a  

^a MAURIZIANO HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Alcohol consumption; Chronic hepatitis C; Interferon therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA INTERFERON; CARBOHYDRATE; TRANSFERRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK;

ADULT; ALCOHOL DRINKING; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; ODDS RATIO; TREATMENT OUTCOME;

EID: 0036904004     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00360.x     Document Type: Article

References (35)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chornic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR DOSVIRC Groups. Lancet 1997; 349: 825-883.
2. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995; 15: 64-69.
3. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C. Results of large, prospective cohort study. Hepatology 1998; 28: 1687-1695.
4. Tinè F, Magrin S, Craxi A et al. Interferon for chronic non-A, non-B hepatitis: A meta analysis of randomized clinical trials. J Hepatol 1991; 13: 192-199.
5. Hoofnagle JH, Lau D. Chronic viral hepatitis - Benefits of current therapies. N Engl J Med 1996; 334: 1470-1471.
6. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pre-treatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
7. Saracco G, Rizzetto M. Predictors of response to interferon therapy. Dig Dis Sci 1994; 39: 977-982.
8. Mabee CL, Crippin JS, Lee WM. Review article: Interferon and hepatitis C - Factors predicting therapeutic outcome. Aliment Pharmacol Ther 1998; 12: 509-518.
9. Okazaki T, Yoshihara H, Suzuki K et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between drinkers and non drinkers. Scand J Gastroenterol 1994; 29: 1039-1043.
10. Oshita M, Hayashi N, Kasahara A et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20: 1115-1120.
11. Ohnishi K, Matsuo S, Matsutani K et al. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-1379.
12. Mochida S, Onishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996; 20: 371A-377A.
13. Loguercio C, Di Pierro M, Di Marino MP et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000; 35: 296-301.
14. Agarwal DP, Harada S, Goedde HW. Racial differences in biological sensitivity to ethanol: The role of alcohol dehydrogenase and aldehyde dehydrogenase isoenzymes. Alcohol Clin Exp Res 1981; 1: 12-6.
15. Aricò S, Galatola G, Tabone M, Corrao G, Torchio P, Valenti M. The measure of lifetime alcohol consumption in cirrhotic patients: Reproducibility and clinical relevance. Liver 1995; 15: 202-208.
16. Stibler H. Carbohydrate deficient transferrin in serum: A new marker of potentially harmful alcohol consumption. Clin Chem 1991; 37: 2029-2037.
17. Wolfe L, Tamatsukuri S, Sayada C, Ryff JC. Detection of HCV RNA in serum using a single-tube, single-enzyme PCR in combination with a colorimetric microwell assay. In: Groupe Francais d'Etudes Moleculaires Des Hepatites (GEMHEP). Hepatitis C Virus: New Diagnostic Tools. Paris: John Libbey Eurotext, 1994, 83-94.
18. Urdea MS. Quantification of hepatitis C virus RNA. clinical applications of the branched DNA assay. In: Groupe Francais d'Etudes Moleculaires Des Hepatites (GEMHEP). Hepatitis C Virus: Genetic Heterogeneity and Viral Load. Paris: John Libbey Eurotext, 1997, 73-78.
19. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J General Virol 1993; 74: 1093-1102.
20. Knodell R, Ishak K, Black W et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
21. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
22. Pares A, Barrera JM, Caballeria J et al. Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury. Hepatology 1990; 12: 1295-1299.
23. Nalpas B, Thiers V, Pol S et al. Hepatitis C viremia and HCV antibodies in alcoholics. J Hepatol 1992; 14: 381-384.
24. Tabone M, Galatola G, Corrao G, Aricò S. Anti-HCV antibodies in patients with chronic liver disease and different amounts of alcohol intake: A multivariate analysis. Eur J Gastroenterol Hepatol 1993; 5: 749-754.
25. Pessione F, Degos F, Marcellin P et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717-1722.
26. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
27. Clot P, Tabone M, Aricò S, Albano E. Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake. Gut 1994; 35: 1637-1643.
28. Clot P, Bellomo G, Tabone M, Aricò S, Albano E. Detection of antibodies against proteins modified by hydroxyethyl free radicals in patients with alcoholic cirrhosis. Gastroenterology 1995; 108: 201-207.
29. Clot P, Albano E, Eliason E et al. Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology 1996; 111: 206-216.
30. Clot P, Parola M, Bellomo G et al. Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. Gastroenterology 1997; 113: 265-276.
31. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22: 364-369.
32. Zylberberg H, Fontaine H, Thepot V, Nalpas B, Brechot C, Pol S. Triggering of acute alcoholic hepatitis by α-interferon therapy. J Hepatol 1999; 30: 722-725.
33. Sherman KE, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 1999; 30: 265-270.
34. Geissler M, Gesien A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. J Immunol 1997; 159: 5107-5113.
35. Szabo G, Catalano D, Bellerose G, Mandrekar P. Interferon alpha and alcohol augment nuclear regolatory factor-kappaB activation in HepG2 cells, and interferon alpha increases pro-inflammatory cytokine production. Alcohol Clin Exp Res 2001; 25: 1188-1197.